144 related articles for article (PubMed ID: 3858014)
1. Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia.
Pearson AD; Craft AW; Eastham EJ; Aherne GW; Littleton P; Pearson GL; Campbell AN
Cancer Chemother Pharmacol; 1985; 14(3):211-5. PubMed ID: 3858014
[TBL] [Abstract][Full Text] [Related]
2. Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Dempsey SI; Bridges JM; Glasgow JF
Br J Cancer; 1980 Oct; 42(4):613-5. PubMed ID: 6934003
[No Abstract] [Full Text] [Related]
3. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?
Pinkerton CR; Welshman SG; Glasgow JF; Bridges JM
Lancet; 1980 Nov; 2(8201):944-6. PubMed ID: 6107590
[TBL] [Abstract][Full Text] [Related]
4. Small bowel function in acute lymphoblastic leukaemia.
Pearson AD; Craft AW; Pledger JV; Eastham EJ; Laker MF; Pearson GL
Arch Dis Child; 1984 May; 59(5):460-5. PubMed ID: 6428327
[TBL] [Abstract][Full Text] [Related]
5. Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia?
Pinkerton CR; Glasgow JF; Bridges JM; Welshman SG
Br Med J (Clin Res Ed); 1981 Apr; 282(6272):1276-7. PubMed ID: 6784815
[No Abstract] [Full Text] [Related]
6. Methotrexate absorption in children with acute lymphoblastic leukemia.
Craft AW; Rankin A; Aherne W
Cancer Treat Rep; 1981; 65 Suppl 1():77-81. PubMed ID: 6948609
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Kelly JG; Shanks RG; Bridges JM
Cancer Chemother Pharmacol; 1982 Dec; 10(1):36-9. PubMed ID: 6961972
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.
Pearson AD; Mills S; Amineddine HA; Long DR; Craft AW; Chessells JM
Cancer Chemother Pharmacol; 1987; 20(3):243-7. PubMed ID: 3315283
[TBL] [Abstract][Full Text] [Related]
9. Modification of oral methotrexate absorption in children with leukemia.
Mahony MJ; Murphy MS; Wadsworth J; Mott MG
Cancer Chemother Pharmacol; 1984; 12(2):131-3. PubMed ID: 6583027
[TBL] [Abstract][Full Text] [Related]
10. Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia.
Beach BJ; Woods WG; Howell SB
Am J Pediatr Hematol Oncol; 1981; 3(2):115-9. PubMed ID: 6975580
[TBL] [Abstract][Full Text] [Related]
11. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
Borsi JD; Moe PJ
Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia.
Craft AW; Kay H; Lawson DN; McElwain TJ
Br Med J; 1977 Dec; 2(6101):1511-2. PubMed ID: 271033
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia.
Borsi JD; Revesz T; Schuler D
Cancer Chemother Pharmacol; 1987; 19(3):261-4. PubMed ID: 3472677
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral methotrexate in children.
Balis FM; Savitch JL; Bleyer WA
Cancer Res; 1983 May; 43(5):2342-5. PubMed ID: 6572562
[TBL] [Abstract][Full Text] [Related]
15. Measurement of small intestinal transit time in children.
Murphy MS; Nelson R; Eastham EJ
Acta Paediatr Scand; 1988 Nov; 77(6):802-6. PubMed ID: 3207016
[TBL] [Abstract][Full Text] [Related]
16. Small intestinal permeability and orocaecal transit time in cystic fibrosis.
Dalzell AM; Freestone NS; Billington D; Heaf DP
Arch Dis Child; 1990 Jun; 65(6):585-8. PubMed ID: 2116115
[TBL] [Abstract][Full Text] [Related]
17. [Role of motility in intestinal transit and absorption].
Fioramonti J; Buéno L
Presse Med; 1989 Feb; 18(6):249-54. PubMed ID: 2522219
[TBL] [Abstract][Full Text] [Related]
18. Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls.
Chander Roland B; Garcia-Tsao G; Ciarleglio MM; Deng Y; Sheth A
J Clin Gastroenterol; 2013; 47(10):888-93. PubMed ID: 23632359
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the Effect of Intestinal Permeability Probes (Lactulose And Mannitol) and Other Liquids on Digesta Residence Times in Various Segments of the Gut Determined by Wireless Motility Capsule: A Randomised Controlled Trial.
Sequeira IR; Lentle RG; Kruger MC; Hurst RD
PLoS One; 2015; 10(12):e0143690. PubMed ID: 26629926
[TBL] [Abstract][Full Text] [Related]
20. Intestinal-transit and lactose intolerance in chronic alcoholics.
Keshavarzian A; Iber FL; Dangleis MD; Cornish R
Am J Clin Nutr; 1986 Jul; 44(1):70-6. PubMed ID: 3728351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
